Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin

scientific article

Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1005846018
P356DOI10.1038/SJ.LEU.2403899
P698PubMed publication ID16079892
P5875ResearchGate publication ID7679893

P50authorHans Guenter DrexlerQ66431272
Wilhelm DirksQ73011398
Hilmar QuentmeierQ92502255
P2093author name stringBolli N
Falini B
Mecucci C
Macleod RA
Liso A
Nicoletti I
Martelli MF
Martelli MP
Bigerna B
Pucciarini A
Mannucci R
P2860cites workPhysical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23Q24629309
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotypeQ27824827
Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cellsQ27860599
ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathwayQ28506702
Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localizationQ28572689
Major nucleolar proteins shuttle between nucleus and cytoplasmQ29620425
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemiaQ34313643
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistryQ34487204
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual diseaseQ34524219
The role of nucleophosmin in centrosome duplicationQ34526870
The molecular basis of leukemiaQ35961770
FLT3 mutations in acute myeloid leukemia cell linesQ40610364
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its functionQ41036948
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenanceQ58882381
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)Q72722889
Mapping the functional domains of nucleolar protein B23Q73829236
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemiaQ74025358
NPM mutations in acute myelogenous leukemiaQ81296162
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotypeQ81712971
P4510describes a project that usesOCI-AML-3Q54931742
P433issue10
P921main subjectcell lineQ21014462
P304page(s)1760-1767
P577publication date2005-10-01
P1433published inLeukemiaQ6534498
P1476titleCell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin
P478volume19

Reverse relations

cites work (P2860)
Q383243841-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1).
Q42806442A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Q38427010A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis
Q60171386A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia
Q41072362Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells
Q92017565Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway
Q91768661Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
Q37514846Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Q41964663An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus.
Q44404888Analysis of NPM1 gene mutations in Chinese adults with acute myeloid leukemia
Q37603441Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
Q45071683Benznidazole modulates cell proliferation in acute leukemia cells.
Q100526251CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia
Q33800539Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
Q34333634Cytoplasmic FANCA-FANCC complex interacts and stabilizes the cytoplasm-dislocalized leukemic nucleophosmin protein (NPMc)
Q35796956Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent
Q38947913DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML
Q35857472Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia.
Q34364350Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Q24652323Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
Q38960308Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate
Q92847577Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
Q90669604Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
Q38778620Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells
Q38084903FOX(M1) News—It Is Cancer
Q39353165FOXM1 in Cancer: Interactions and Vulnerabilities
Q39129437Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Q33555287Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Q46300745Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Q35940547Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.
Q37226490HEXIM1, a New Player in the p53 Pathway
Q33572309High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
Q31037798Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells
Q49993172INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia
Q38722849Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia
Q37812868Immunohistochemical Surrogates for Genetic Alterations of CCDN1, PML, ALK, and NPM1 Genes in Lymphomas and Acute Myeloid Leukemia
Q37697853Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
Q33327492Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations
Q36298896Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants
Q40330808JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
Q38698012Long noncoding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
Q57177521Low frequency of DNMT3A mutations in pediatric AML and the identification of the OCI-AML3 cell line as an in vitro model
Q38862452MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Q41614195Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications
Q38245417Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.
Q40980425NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells
Q44702333Novel NPM1 mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia
Q51439944Nuclear FOXM1 drives chemoresistance in AML.
Q28589317Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma
Q35842155Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells
Q38084251Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
Q89768685Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
Q91287169Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML
Q33861884Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro
Q38426552Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Q36206410Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Q38834968Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia.
Q37334404Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.
Q92002013Quantitative Assay of Mutated Nucleophosmin in Acute Myeloid Leukemia
Q41960009Reactivating the ARF-p53 axis in AML cells by targeting ULF.
Q92669428Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment
Q92001688Role of Nucleophosmin Gene Mutation in Leukemogenesis of Acute Myeloid Leukemia
Q42710172Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib
Q37045295Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
Q58732929Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing
Q39378248Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia
Q35377418Targeting AML through DR4 with a novel variant of rhTRAIL
Q27851657Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Q84920949The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations
Q92989510The Role of Forkhead Box Proteins in Acute Myeloid Leukemia
Q54267390The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia
Q84583451The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients
Q35060679The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan
Q37687642The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b
Q38262117The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
Q24301836Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses
Q35837541miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.
Q39392644p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.

Q54931742OCI-AML-3described by sourceP1343

Search more.